Johnson & Johnson (NYSE: JNJ) announced it will present 18 abstracts featuring data from its neuropsychiatry portfolio at the American Psychiatric Association (APA) Annual Meeting (May 16-20, San Francisco) and the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (May 26-29, Miami).

The presentations will include data on CAPLYTA (lumateperone), seltorexant, SPRAVATO (esketamine) nasal spray, and long-acting injectable treatments for neuropsychiatric disorders including major depressive disorder, treatment-resistant depression, and schizophrenia.

Key presentations include long-term CAPLYTA data evaluating relapse prevention in schizophrenia at the APA meeting. At the ASCP meeting, the company will present Phase 3 data on seltorexant, an investigational orexin-2 receptor antagonist being studied as adjunctive therapy for adults with major depressive disorder and insomnia symptoms.

Additional data will cover CAPLYTA analyses from Phase 3 studies in major depressive disorder, SPRAVATO post-hoc analyses from the SUSTAIN-1 study in treatment-resistant depression, and recommendations for long-acting injectable treatments in schizophrenia.

CAPLYTA is approved as adjunctive therapy with antidepressants for major depressive disorder, for schizophrenia, and for depressive episodes associated with bipolar disorder. SPRAVATO is approved for treatment-resistant depression and for major depressive disorder with acute suicidal ideation or behavior when used with oral antidepressants.

The presentations span research across multiple neuropsychiatric conditions, highlighting data from the company's approved treatments and investigational compounds in development.